Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer.

ABSTRACT: Estrogen receptor-positive (ER+) breast cancer is the most common form of breast cancer. Antiestrogens were the first therapy aimed at treating this subtype, but resistance to these warranted the development of a new treatment option. CDK4/6 inhibitors address this problem by halting cell cycle progression in ER+ cells, and have proven to be successful in the clinic. Unfortunately, both intrinsic and acquired resistance to CDK4/6 inhibitors are common. Numerous mechanisms of how resistance occurs have been identified to date, including the activation of prominent growth signaling pathways, the loss of tumor-suppressive genes, and noncanonical cell cycle function. Many of these have been successfully targeted and demonstrate the ability to overcome resistance to CDK4/6 inhibitors in preclin

SUBMITTER: Scheidemann ER 

PROVIDER: S-EPMC8625090 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature